Bio-Rad Laboratories, Inc. (BIO - Free Report) has been witnessing strength in international markets. Further, strong key product lines across major geographic regions buoy optimism. The stock currently carries a Zacks Rank #2 (Buy).
Over the past year, Bio-Rad has outperformed its industry. The stock has gained 21.7% compared with the industry’s 5.2% rise.
Bio-Rad exited the third quarter of 2021 with better-than-expected results. The company witnessed solid top-and bottom-line growth in the reported quarter. An increase in demand for Droplet Digital PCR products along with core qPCR business growth, driven by strong uptake of the latest generation CFX Opus platform, is encouraging. The uptick in the Clinical Diagnostics arm, driven by higher utilization in lab operations as businesses recover from the COVID-19 pandemic, is encouraging as well. The raised 2021 revenue guidance is indicative of the continuation of this bullish trend.
Buy 5 Stocks BEFORE Election Day
Biden or Trump? Zacks is releasing a FREE Special Report, Profit from the 2024 Presidential Election (no matter who wins).
Since 1950, presidential election years have been strong for the market. This report names 5 timely stocks to ride the wave of electoral excitement.
They include a medical manufacturer that gained +11,000% in the last 15 years… a rental company absolutely crushing its sector… an energy powerhouse planning to grow its already large dividend by 25%... an aerospace and defense standout that just landed a potentially $80 billion contract… and a giant chipmaker building huge plants in the U.S.
Don’t Wait. Download FREE >>
Bio-Rad Laboratories, Inc. (BIO - Free Report) has been witnessing strength in international markets. Further, strong key product lines across major geographic regions buoy optimism. The stock currently carries a Zacks Rank #2 (Buy).
Over the past year, Bio-Rad has outperformed its industry. The stock has gained 21.7% compared with the industry’s 5.2% rise.
Bio-Rad exited the third quarter of 2021 with better-than-expected results. The company witnessed solid top-and bottom-line growth in the reported quarter. An increase in demand for Droplet Digital PCR products along with core qPCR business growth, driven by strong uptake of the latest generation CFX Opus platform, is encouraging. The uptick in the Clinical Diagnostics arm, driven by higher utilization in lab operations as businesses recover from the COVID-19 pandemic, is encouraging as well. The raised 2021 revenue guidance is indicative of the continuation of this bullish trend.
Buy 5 Stocks BEFORE Election Day
Biden or Trump? Zacks is releasing a FREE Special Report, Profit from the 2024 Presidential Election (no matter who wins).
Since 1950, presidential election years have been strong for the market. This report names 5 timely stocks to ride the wave of electoral excitement.
They include a medical manufacturer that gained +11,000% in the last 15 years… a rental company absolutely crushing its sector… an energy powerhouse planning to grow its already large dividend by 25%... an aerospace and defense standout that just landed a potentially $80 billion contract… and a giant chipmaker building huge plants in the U.S.
Don’t Wait. Download FREE >>
Get the latest research report on LH - FREE
Get the latest research report on BIO - FREE
Get the latest research report on CHE - FREE
Get the latest research report on MEDP - FREE